公开(公告)号：US09249097B2

公开(公告)日：2016-02-02

申请号：US14109259

申请日：2013-12-17

申请人： AZIENDE CHIM. RIUN. ANG. FRANC. A.C.R.A.F. S.p.A.

发明人： Maria Alessandra Alisi ,  Nicola Cazzolla ,  Isabella Coletta ,  Patrizia Dragone ,  Guido Furlotti ,  Barbara Garofalo ,  Angelo Guglielmotti ,  Giorgina Mangano ,  Caterina Maugeri

IPC分类号： C07D209/88

CPC分类号： C07D209/88

摘要： The present invention relates to novel benzoyl derivatives of 3-aminocarbazole, to a pharmaceutical composition containing them, to a method for preparing them and to the use of such compounds for the production of a drug that is useful in the treatment or prevention of disturbances associated with the production of prostaglandin E2 (PGE2), for instance inflammatory processes, pain, fever, tumours, Alzheimer's disease and atherosclerosis.

摘要翻译： 本发明涉及3-氨基咔唑的新型苯甲酰基衍生物，其含有它们的药物组合物，其制备方法和用于制备可用于治疗或预防相关疾病的药物的用途 产生前列腺素E2（PGE2），例如炎症过程，疼痛，发烧，肿瘤，阿尔茨海默病和动脉粥样硬化。

公开(公告)号：US09255073B2

公开(公告)日：2016-02-09

申请号：US13898950

申请日：2013-05-21

申请人： AZIENDE CHIM. RIUN. ANG. FRANC. A.C.R.A.F. S.p.A.

发明人： Angelo Guglielmotti ,  Guido Furlotti ,  Giorgina Mangano ,  Nicola Cazzolla

IPC分类号： A61K31/415 ,  A01N43/56 ,  C07D231/56 ,  C07D209/00 ,  C07D231/54 ,  C07D401/12 ,  C07D295/088

CPC分类号： C07D231/56 ,  C07D231/54 ,  C07D295/088 ,  C07D401/12

摘要： The present invention relates to novel 1-benzyl-3-hydroxymethylindazole derivatives according to formula (I) described in the claims, and to a pharmaceutical composition comprising them, together with a pharmaceutically acceptable vehicle. In addition, the present invention relates to the use of 1-benzyl-3-hydroxymethylindazole derivatives for the preparation of a pharmaceutical composition that is active in the treatment of diseases based on the expression of MCP-1, CX3CR1 and p40, and to their use in a method for treating or preventing diseases based on the expression of MCP-1, CX3CR1 and p40.

摘要翻译： 本发明涉及权利要求中记载的式（I）所示的新颖的1-苄基-3-羟基甲基吲唑衍生物，以及包含它们的药物组合物以及药学上可接受的载体。 此外，本发明涉及1-苄基-3-羟甲基吲唑衍生物在制备基于MCP-1，CX3CR1和p40的表达的疾病治疗中有效的药物组合物的用途，以及它们 用于基于MCP-1，CX3CR1和p40表达的治疗或预防疾病的方法。